NanoViricides, Inc. (NYSE American: NNVC) announced positive results from a juvenile mouse study evaluating the safety, tolerability and toxicity of its broad-spectrum antiviral drug NV-387, supporting its potential advancement into pediatric clinical trials. The 12-day repeated-dose study found NV-387 Oral Gummies were well tolerated at all tested dose levels, with no mortality, systemic toxicity or treatment-related adverse effects. The highest tested dose of 3,690 mg/kg/day was established as the “No Observed Adverse Effect Level” (NOAEL), with no maximum tolerated dose identified.
The company believes the findings could support pediatric enrollment in future clinical trials for Ebola, Mpox and measles, subject to further clinical development and regulatory requirements. NV-387 is currently being evaluated in Phase II clinical trials for Ebola and Mpox in the Democratic Republic of Congo. The drug has also received U.S. Food and Drug Administration orphan drug and rare pediatric disease designations for measles.
Separately, NanoViricides disclosed that its fiscal 2026 annual report included an auditor statement expressing substantial doubt about its ability to continue as a going concern. The company is pursuing potential nondilutive funding for clinical development while maintaining access to equity-based financing, including an at-the-market share offering facility.
The positive juvenile safety data could be a significant step for NanoViricides, as it may allow the company to expand NV-387’s development into pediatric populations, a critical unmet need for infectious diseases like Ebola, Mpox and measles. However, the going concern warning underscores the financial risks facing the clinical-stage company as it seeks to advance its pipeline. For investors, the news presents a mixed picture: scientific progress tempered by funding uncertainty.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates is based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company’s lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and measles. Another advanced candidate is NV-HHV-1 for shingles.
To view the full press release, visit https://ibn.fm/5QClt. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. For more information about NanoViricides, visit www.nanoviricides.com.
MissionIR, a specialized communications platform, distributed the announcement. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution.
